| 
A1CNow+ provides consistent, lab accurate results without the use of expensive capital equipment.
This system is certified and meets all standards required for certification by the National Glycohemoglobin
Standardization Program (NGSP).7
Immediate, face-to-face conuseling about
your patients A1C results may motivate patients to actually
do the things you tell them to do.
Patients who get immediate feedback
may lower their A1C by up to 1%.
Lowering A1C levels reduces the risks
of long term complications.
It's been shown that a 1% reduction
in A1C lowers risk of complications such as eye, kidney
and nerve disease by
40%
Immediate
Results Impacts Treatment Modification |
First
Visit |
With Immediate
Feedback
52% |
With Delayed
Feedback (Lab)
27% |
|
|
|
For
1, 2, or 3 kit
orders, please
click here to go
to our store.
For
orders above 3 kits, or Purchase Orders, please print
out this pdf here.
NEWSFLASH:
Coming Soon a
2-Pack A1c test
Click to
receive info when it is available.
NEW
CPT CODE and INCREASED REIMBURSEMENT RATES FOR
A1cNow+
Average
reimbursement now $21.06 in most areas of the
country.
Even
without diabetes the A1c results can show the
risk of mortality from heart disease.
|
EFFECT OF IMMEDIATE HEMOGLOBIN A1c RESULTS ON TREATMENT DECISIONS IN OFFICE PRACTICE
Andrea Ferenczi, MD A1, Kalpana Reddy, MD A1, Daniel L. Lorber, MD, FACP A2
A1 New York Hospital Medical Center of Queens, Flushing, New, York.
A2 New York Hospital Medical Center of Queens, Flushing, New York and Weill Medical College of Cornell University, New York, New York.
Abstract:
Objective:
To assess the effect of an immediately available hemoglobin A1c (HbA1c) result on glycemic control and physician decisions about pharmacologic therapy in an office practice. Methods: In a 1-year retrospective review of medical records, HbA1c results were analyzed in 115 patients beyond the age of 65 years, who had type 2 diabetes and were referred for the first time to a private endocrinology practice between April 1, 1997, and March 31, 1998. These patients were classified into two groups: group A (N = 93, insured by standard Medicare) had immediate HbA1c results (during the patient encounter) and group B (N = 22, insured by Medicare health maintenance organization [HMO]) had commercial laboratory HbA1c results available within 2 to 3 days. We reviewed the changes in the HbA1c level during the 12-month period and the presence or absence of a change in therapy at each visit. HbA1c levels were measured by ion-exchange low-pressure liquid chromatography in group A and by one of three capitated commercial laboratories (depending on HMO contracts) in group B. Results: At the end of the 12 months, the mean HbA1c decrease was 1.03 - 0.33% in group A and 0.33 - 0.83% in group B. During the first visit, 52% of the patients in group A had pharmacologic treatment interventions, whereas only 27% in group B had such interventions. Conclusion: Rapid availability of the HbA1c results during the clinical encounter improves the ability of the physician to make appropriate therapeutic decisions and results in improved glycemic control.
Read Full Article
If
you would like more information about
using A1CNow+®
in your practice, please
contact us |
A1CNow+ Brochure (PDF)
|
|